Gedea Biotech obtains US-patent covering pHyph for antibiotic-free treatment and prevention of bacterial vaginosis
· Important expansion of patent estate in the largest market for vaginal bacterial infections · pHyph has shown superior safety profile, a cure rate in line with antibiotics and a lower infection recurrence rate Lund, Sweden, April 18, 2023. Swedish women’s health company Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company´s patent application 16/753,899 directed to gluconic acid derivatives for preventing and/or treating bacterial infections. The patent number is US 11,612,584 and the patent can be kept in force until 2038.